Amyris, Inc. has announced plans to acquire Oobli Inc., a Davis, California-based sweet protein developer whose fermentation-based ingredients are designed to help food and beverage brands reduce sugar without sacrificing taste. Amyris, based in Emeryville, California, describes itself as a vertically integrated biomanufacturing company. The deal is intended to combine its strain engineering, manufacturing scale and commercial capabilities with Oobli's protein fermentation expertise.
The acquisition follows Amyris' expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. Amyris said the purchase represents a strategic commercial and technology expansion aimed at accelerating its work in protein- and peptide-based solutions across end markets.
Complementary platforms
Kathy Fortmann, Amyris' chief executive officer, said Oobli offers a commercial and technology platform that complements Amyris' own. Fortmann added that Oobli is positioned to transform how sweetness reaches the market, and that Amyris aims to apply its commercial scale and resources to accelerate that effort. According to Fortmann, combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden what the company can offer in food and beverage, personal care, flavor and fragrance, agriculture and other areas.
Oobli's sweet protein portfolio is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins naturally found in rare fruits and berries near the equator. Oobli says its sweet proteins are the first of their kind in the sugar-reduction category. According to Oobli, they are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, providing sweetness without gut disruption or blood sugar spikes.
Portfolio and regulatory status
Oobli's portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. The company says the ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. According to the announcement, the ingredients could give brands a new tool to reduce sugar across categories including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, as consumer awareness of metabolic health grows.
Ali Wing, Oobli's chief executive officer, said the company had long believed there was a better way to deliver the sweetness consumers love without trade-offs to health and the environment. Wing said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann said biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform addresses sweet taste, sugar reduction and clean label goals together. The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli's portfolio expands within the company.
